A Clinical Study of SI-B001 in Combination With Paclitaxel in the Treatment of Recurrent and Metastatic HNSCC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 22, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

SI-B001

Si-b001 is administered by intravenous drip once a week (QW). The first intravenous infusion is 120 min±10min. If the infusion reaction can be tolerated during the first infusion, the subsequent infusion can be completed in 60-120 min.

DRUG

Paclitaxel

The dosage of paclitaxel was 80mg/m2 QW. SI-B001 and paclitaxel were used on the same day. After SI-B001 infusion, paclitaxel was pretreated and injected for no less than 3 hours.

Trial Locations (7)

200120

Shanghai Oriental Hospital, Shanghai

Unknown

The Second Affiliated Hospital of Guilin Medical University, Guilin

The Affiliated Cancer Hospital of Guizhou Medical University, Guiyang

Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Wuhan

Hunan Cancer Hospital, Changsha

West China Hospital,Sichuan University, Chengdu

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Sichuan Baili Pharmaceutical Co., Ltd.

INDUSTRY